HC Wainwright & Co. Maintains Buy on Acelyrin, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Acelyrin (NASDAQ:SLRN) and raises the price target from $16 to $18.
May 22, 2024 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Acelyrin (NASDAQ:SLRN) and raises the price target from $16 to $18.
The raised price target and maintained Buy rating from a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Acelyrin, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100